Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RPT
2726
Rithm Property Trust
RPT
$99.9M
| $575K | ﹤0.01% |
7,090
| – | – |
|
|
STAB
2727
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
| $569K | ﹤0.01% |
192,716
+157,700
| +450% | +$515K |
|
|
CCIH
2728
DELISTED
Chinacache International Holdings Ltd
CCIH
| $568K | ﹤0.01% |
489,799
+277,699
| +131% | +$341K |
|
2729
Sturm, Ruger & Co
RGR
$600M
| $566K | ﹤0.01% |
9,100
-100,000
| -92% | -$6.21M |
|
|
ELP
2730
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
| $560K | ﹤0.01% |
+190,750
| New | +$660K |
|
2731
Global Water Resources
GWRS
$219M
| $558K | ﹤0.01% |
+56,411
| New | +$516K |
|
2732
Energy Transfer Partners
ET
$72.1B
| $555K | ﹤0.01% |
+30,918
| New | +$550K |
|
2733
First Majestic Silver
AG
$9.26B
| $551K | ﹤0.01% |
66,400
-84,900
| -56% | -$714K |
|
|
SA
2734
Seabridge Gold
SA
$3.5B
| $549K | ﹤0.01% |
51,005
-15,695
| -24% | -$167K |
|
|
STDY
2735
DELISTED
SteadyMed Ltd
STDY
| $546K | ﹤0.01% |
86,700
+65,100
| +301% | +$443K |
|
2736
MediWound
MDWD
$179M
| $545K | ﹤0.01% |
11,443
+643
| +6% | +$29.9K |
|
2737
News Corp Class B
NWS
$17.7B
| $543K | ﹤0.01% |
38,392
-289,308
| -88% | -$3.89M |
|
|
GLBR
2738
DELISTED
Global Brokerage, Inc. Class A Common Stock
GLBR
| $542K | ﹤0.01% |
271,230
+4,500
| +2% | +$9.26K |
|
2739
Marten Transport
MRTN
$1.22B
| $540K | ﹤0.01% |
+49,293
| New | +$492K |
|
|
PRTY
2740
DELISTED
Party City Holdco Inc.
PRTY
| $540K | ﹤0.01% |
34,500
-80,400
| -70% | -$1.24M |
|
|
JBTM
2741
JBT Marel
JBTM
$6.15B
| $539K | ﹤0.01% |
5,500
-115,400
| -95% | -$10.2M |
|
2742
CrossAmerica Partners
CAPL
$889M
| $536K | ﹤0.01% |
21,000
-65,994
| -76% | -$1.65M |
|
|
CWBC
2743
Community West Bancshares
CWBC
$706M
| $536K | ﹤0.01% |
24,200
-31,800
| -57% | -$677K |
|
|
XNET
2744
Xunlei
XNET
$316M
| $536K | ﹤0.01% |
165,304
-27,346
| -14% | -$97.5K |
|
|
ATTO
2745
DELISTED
Atento S.A.
ATTO
| $533K | ﹤0.01% |
9,508
+3,739
| +65% | +$186K |
|
2746
Hilltop Holdings
HTH
$2.25B
| $532K | ﹤0.01% |
20,284
-44,100
| -68% | -$1.17M |
|
|
TTNP
2747
DELISTED
Titan Pharmaceuticals
TTNP
| $530K | ﹤0.01% |
77
+11
| +17% | +$102K |
|
|
DTRM
2748
DELISTED
Determine, Inc. Common Stock
DTRM
| $530K | ﹤0.01% |
201,614
+51,800
| +35% | +$173K |
|
2749
Integra LifeSciences
IART
$1.35B
| $529K | ﹤0.01% |
9,700
-163,960
| -94% | -$7.83M |
|
2750
El Pollo Loco
LOCO
$463M
| $526K | ﹤0.01% |
+38,000
| New | +$506K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.